| __timestamp | Ligand Pharmaceuticals Incorporated | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 10811000 |
| Thursday, January 1, 2015 | 24378000 | 33001000 |
| Friday, January 1, 2016 | 26621000 | 64936000 |
| Sunday, January 1, 2017 | 28653000 | 99909000 |
| Monday, January 1, 2018 | 37734000 | 127724000 |
| Tuesday, January 1, 2019 | 41884000 | 161524000 |
| Wednesday, January 1, 2020 | 64435000 | 182933000 |
| Friday, January 1, 2021 | 57483000 | 219982000 |
| Saturday, January 1, 2022 | 70062000 | 278139000 |
| Sunday, January 1, 2023 | 52790000 | 309799000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Ultragenyx Pharmaceutical Inc. and Ligand Pharmaceuticals Incorporated have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Ultragenyx's SG&A expenses surged by approximately 2,765%, reflecting its aggressive growth strategy. In contrast, Ligand's expenses increased by about 134%, indicating a more conservative approach.
Ultragenyx's spending peaked in 2023, with expenses reaching nearly 310 million, a stark contrast to its modest 10.8 million in 2014. Ligand, while more stable, saw its highest expenditure in 2022, with a 210% increase from 2014. This divergence highlights differing strategic priorities: Ultragenyx's focus on rapid expansion versus Ligand's steady, controlled growth. As the pharmaceutical industry evolves, these spending patterns offer insights into each company's operational focus and market positioning.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Exelixis, Inc. vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Corcept Therapeutics Incorporated vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Cytokinetics, Incorporated vs Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and MorphoSys AG
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Agios Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?